| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1995;91:10-15.)
© 1995 American Heart Association, Inc.
Articles |
Probucol Protects Against Adriamycin Cardiomyopathy Without Interfering With Its Antitumor Effect
From the Division of Cardiovascular Sciences (N.S.-I., M.H., P.K.S.), Department of Physiology, and St Boniface General Hospital Research Center; and the Department of Immunology (D.A.C.), Faculty of Medicine, University of Manitoba, Winnipeg, Canada.
Correspondence to Dr P.K. Singal, St Boniface General Hospital Research Center, Rm R3022, 351 Tache Ave, Winnipeg, Manitoba, Canada R2H 2A6.
Background The usefulness of adriamycin (ADR), a potent antitumor antibiotic, is limited by the development of life-threatening cardiomyopathy and congestive heart failure. Subcellular changes leading to heart failure are suggested to be mediated by a drug-induced increase in free radicals and lipid peroxidation. In an earlier study, concurrent treatment with probucol (PROB), a lipid-lowering drug with strong antioxidant properties, was shown to offer only partial protection against ADR cardiomyopathy. The present study had two aims: to determine whether this protective effect can be improved further by extended treatment with PROB, and to determine whether PROB affects the antitumor properties of ADR.
Methods and Results ADR (cumulative dose, 15 mg/kg body wt) was administered in rats in six equal injections (IP) over a period of 2 weeks. Three weeks after the end of treatment, cardiomyopathy and congestive heart failure were characterized by ascites, congested liver, depressed cardiac function, elevated left ventricular end-diastolic pressure, and myocardial cell damage. Myocardial glutathione peroxidase (GSHPx) activity was decreased and lipid peroxidation was increased. Administration of PROB (cumulative dose, 120 mg/kg body wt) in 12 equal injections (IP), before and concurrent with ADR, completely prevented these cardiomyopathic changes, normalized left ventricular function, lowered mortality, and eliminated ascites. Treatment with PROB was also accompanied by an increase in myocardial GSHPx and superoxide dismutase activities with a concomitant decrease in lipid peroxidation. Tumor regression in syngeneic DBA/2 mice inoculated with L5178Y-F9 lymphoma cells in the ADR+PROB group was significant and comparable to the ADR group.
Conclusions These data show for the first time that PROB can provide complete protection against ADR cardiomyopathy without interfering with antitumor properties of the drug. This protective effect of PROB may be related to the maintenance of the antioxidant status of the heart.
Key Words: antioxidants • heart failure
This article has been cited by other articles:
 |
|
 |
|
  K Yamahara, K D Min, H Tomoike, K Kangawa, S Kitamura, and N Nagaya Pathological role of angiostatin in heart failure: an endogenous inhibitor of mesenchymal stem-cell activation Heart, February 1, 2009; 95(4): 283 - 289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Y. Wonders, D. S. Hydock, C. M. Schneider, and R. Hayward Acute Exercise Protects Against Doxorubicin Cardiotoxicity Integr Cancer Ther, September 1, 2008; 7(3): 147 - 154. [Abstract] [PDF]
|
|
|
|
 |
|
 L. Gianni, E. H. Herman, S. E. Lipshultz, G. Minotti, N. Sarvazyan, and D. B. Sawyer Anthracycline Cardiotoxicity: From Bench to Bedside J. Clin. Oncol., August 1, 2008; 26(22): 3777 - 3784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Nazam Ansari, U Bhandari, and K. Pillai Protective role of curcumin in myocardial oxidative damage induced by isoproterenol in rats Human and Experimental Toxicology, December 1, 2007; 26(12): 933 - 938. [Abstract] [PDF]
|
|
|
|
 |
|
 L. Li, Q. Pan, W. Han, Z. Liu, L. Li, and X. Hu Schisandrin B Prevents Doxorubicin-Induced Cardiotoxicity via Enhancing Glutathione Redox Cycling Clin. Cancer Res., November 15, 2007; 13(22): 6753 - 6760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Turakhia, C. D. Venkatakrishnan, K. Dunsmore, H. Wong, P. Kuppusamy, J. L. Zweier, and G. Ilangovan Doxorubicin-induced cardiotoxicity: direct correlation of cardiac fibroblast and H9c2 cell survival and aconitase activity with heat shock protein 27 Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H3111 - H3121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Fajardo and D. Bernstein Endocannabinoid Inhibition: A New Cardioprotective Strategy Against Doxorubicin Cardiotoxicity J. Am. Coll. Cardiol., August 7, 2007; 50(6): 537 - 539. [Full Text] [PDF]
|
|
|
|
|
|
C. D. Venkatakrishnan, A. K. Tewari, L. Moldovan, A. J. Cardounel, J. L. Zweier, P. Kuppusamy, and G. Ilangovan Heat shock protects cardiac cells from doxorubicin-induced toxicity by activating p38 MAPK and phosphorylation of small heat shock protein 27 Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H2680 - H2691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Christiansen and R. Autschbach Doxorubicin in experimental and clinical heart failure. Eur. J. Cardiothorac. Surg., October 1, 2006; 30(4): 611 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. G. Neilan, G. A. Doherty, G. Chen, C. Deflandre, H. McAllister, R. K. Butler, S. E. McClelland, E. Kay, L. R. Ballou, and D. J. Fitzgerald Disruption of COX-2 modulates gene expression and the cardiac injury response to doxorubicin Am J Physiol Heart Circ Physiol, August 1, 2006; 291(2): H532 - H536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. M. Zornoff, L. S. Matsubara, B. B. Matsubara, M. P. Okoshi, K. Okoshi, M. Dal Pai-Silva, R. F. Carvalho, A. C. Cicogna, C. R. Padovani, E. L. Novelli, et al. Beta-Carotene Supplementation Attenuates Cardiac Remodeling Induced by One-Month Tobacco-Smoke Exposure in Rats Toxicol. Sci., March 1, 2006; 90(1): 259 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Chicco, D. S. Hydock, C. M. Schneider, and R. Hayward Low-intensity exercise training during doxorubicin treatment protects against cardiotoxicity J Appl Physiol, February 1, 2006; 100(2): 519 - 527. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. George, D. Wexler, A. Roth, T. Barak, D. Sheps, and G. Keren Usefulness of anti-oxidized LDL antibody determination for assessment of clinical control in patients with heart failure Eur J Heart Fail, January 1, 2006; 8(1): 58 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Takaseya, M. Ishimatsu, E. Tayama, A. Nishi, T. Akasu, and S. Aoyagi Mechanical unloading improves intracellular Ca2+ regulation in rats with doxorubicin-induced cardiomyopathy J. Am. Coll. Cardiol., December 7, 2004; 44(11): 2239 - 2246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity Pharmacol. Rev., June 1, 2004; 56(2): 185 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Shiomi, H. Tsutsui, H. Matsusaka, K. Murakami, S. Hayashidani, M. Ikeuchi, J. Wen, T. Kubota, H. Utsumi, and A. Takeshita Overexpression of Glutathione Peroxidase Prevents Left Ventricular Remodeling and Failure After Myocardial Infarction in Mice Circulation, February 3, 2004; 109(4): 544 - 549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Yuan, K. Shioji, Y. Kihara, H. Takenaka, Y. Onozawa, and C. Kishimoto Cardioprotective effects of carvedilol on acute autoimmune myocarditis: anti-inflammatory effects associated with antioxidant property Am J Physiol Heart Circ Physiol, January 1, 2004; 286(1): H83 - H90. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Pacher, L. Liaudet, P. Bai, J. G. Mabley, P. M. Kaminski, L. Virag, A. Deb, E. Szabo, Z. Ungvari, M. S. Wolin, et al. Potent Metalloporphyrin Peroxynitrite Decomposition Catalyst Protects Against the Development of Doxorubicin-Induced Cardiac Dysfunction Circulation, February 18, 2003; 107(6): 896 - 904. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Shioji, C. Kishimoto, H. Nakamura, H. Masutani, Z. Yuan, S.-i. Oka, and J. Yodoi Overexpression of Thioredoxin-1 in Transgenic Mice Attenuates Adriamycin-Induced Cardiotoxicity Circulation, September 10, 2002; 106(11): 1403 - 1409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Nakamura, K. Egashira, Y. Machida, S. Hayashidani, M. Takeya, H. Utsumi, H. Tsutsui, and A. Takeshita Probucol Attenuates Left Ventricular Dysfunction and Remodeling in Tachycardia-Induced Heart Failure: Roles of Oxidative Stress and Inflammation Circulation, July 16, 2002; 106(3): 362 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Liu, Z. Chen, C. C. Chua, Y.-S. Ma, G. A. Youngberg, R. Hamdy, and B. H. L. Chua Melatonin as an effective protector against doxorubicin-induced cardiotoxicity Am J Physiol Heart Circ Physiol, July 1, 2002; 283(1): H254 - H263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. T. Sia, N. Lapointe, T. G. Parker, J. N. Tsoporis, C. F. Deschepper, A. Calderone, A. Pourdjabbar, J.F. Jasmin, J.F. Sarrazin, P. Liu, et al. Beneficial Effects of Long-Term Use of the Antioxidant Probucol in Heart Failure in the Rat Circulation, May 28, 2002; 105(21): 2549 - 2555. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Suzuki, B. Murtuza, L. Heslop, J. E. Morgan, R. T. Smolenski, N. Suzuki, T. A. Partridge, and M. H. Yacoub Single fibers of skeletal muscle as a novel graft for cell transplantation to the heart J. Thorac. Cardiovasc. Surg., May 1, 2002; 123(5): 984 - 992. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. GILL, R. MESTRIL, and A. SAMALI Losing heart: the role of apoptosis in heart disease--a novel therapeutic target? FASEB J, February 1, 2002; 16(2): 135 - 146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. T. Sia, T. G. Parker, P. Liu, J. N. Tsoporis, A. Adam, and J. L. Rouleau Improved post-myocardial infarction survival with probucol in rats: Effects on left ventricular function, morphology, cardiac oxidative stress and cytokine expression J. Am. Coll. Cardiol., January 2, 2002; 39(1): 148 - 156. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Suzuki, B. Murtuza, N. Suzuki, R. T. Smolenski, and M. H. Yacoub Intracoronary Infusion of Skeletal Myoblasts Improves Cardiac Function in Doxorubicin-Induced Heart Failure Circulation, September 18, 2001; 104 (2009): I-213 - I-217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Rabelo, K. De Angelis, P. Bock, T. Gatelli Fernandes, F. Cervo, A. Bello Klein, N. Clausell, and M. Claudia Irigoyen Baroreflex Sensitivity and Oxidative Stress in Adriamycin-Induced Heart Failure Hypertension, September 1, 2001; 38(3): 576 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Teraoka, M. Hirano, K. Yamaguchi, and A. Yamashina Progressive cardiac dysfunction in adriamycin-induced cardiomyopathy rats Eur J Heart Fail, December 1, 2000; 2(4): 373 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Li and P. K. Singal Adriamycin-Induced Early Changes in Myocardial Antioxidant Enzymes and Their Modulation by Probucol Circulation, October 24, 2000; 102(17): 2105 - 2110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kinugawa, H. Tsutsui, S. Hayashidani, T. Ide, N. Suematsu, S. Satoh, H. Utsumi, and A. Takeshita Treatment With Dimethylthiourea Prevents Left Ventricular Remodeling and Failure After Experimental Myocardial Infarction in Mice : Role of Oxidative Stress Circ. Res., September 1, 2000; 87(5): 392 - 398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Li, I. Danelisen, A. Bello-Klein, and P. K. Singal Effects of probucol on changes of antioxidant enzymes in adriamycin-induced cardiomyopathy in rats Cardiovasc Res, June 1, 2000; 46(3): 523 - 530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Oskarsson, L. Coppey, R. M. Weiss, and W.-G. Li Antioxidants attenuate myocyte apoptosis in the remote non-infarcted myocardium following large myocardial infarction Cardiovasc Res, February 1, 2000; 45(3): 679 - 687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. K. Seneviratne, T. Li, N. Khaper, and P. K. Singal Effects of methionine on endogenous antioxidants in the heart Am J Physiol Heart Circ Physiol, December 1, 1999; 277(6): H2124 - H2128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K Singal, N. Khaper, V. Palace, and D. Kumar On the role of coenzyme Q10 in cardiovascular diseases Cardiovasc Res, July 1, 1999; 43(1): 250 - 251. [Full Text] [PDF]
|
|
|
|
|
|
G. MINOTTI, G. CAIRO, and E. MONTI Role of iron in anthracycline cardiotoxicity: new tunes for an old song? FASEB J, February 1, 1999; 13(2): 199 - 212. [Abstract] [Full Text]
|
|
|
|
|
|
P. K Singal, N. Khaper, V. Palace, and D. Kumar The role of oxidative stress in the genesis of heart disease Cardiovasc Res, December 1, 1998; 40(3): 426 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. K. Singal and N. Iliskovic Doxorubicin-Induced Cardiomyopathy N. Engl. J. Med., September 24, 1998; 339(13): 900 - 905. [Full Text] [PDF]
|
|
|
|
 |
|
 An Antidote to Adriamycin Cardiotoxicity? Journal Watch Cardiology, March 1, 1995; 1995(301): 15 - 15. [Full Text]
|
|
|
|
 |
|
 AN ANTIDOTE TO ADRIAMYCIN CARDIOTOXICITY? Journal Watch (General), January 20, 1995; 1995(120): 7 - 7. [Full Text]
|
|